Stock listing
OTC:VCNX Vaccinex, Inc. Stock
Follow Vaccinex, Inc. into a list and get an email when it puts out news.
Share price · OTC:VCNX
$0.80 USD -0.10 (-11.1%)
Close on Nov 20, 2026
- Day range
- $0.80 – $1.01 USDNov 20, 2026
- Volume
- 21 sharesNov 20, 2026
- Market cap
- $2.14M USDAt the close on Nov 20, 2026 · price × 2.68M shares outstanding
- 52-week range
- $0.31 – $1.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1,147 USDMedian day 300 shares · 9 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:VCNX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.80 | -0.10 | -11.1% | $1.01 | $1.01 | $0.80 | 21 | |
| $0.90 | -0.10 | -10.0% | $0.85 | $0.90 | $0.78 | 400 | |
| $1.00 | 0.00 | 0.0% | $1.02 | $1.02 | $1.00 | 5,600 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 0 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 104 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 6 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 1,700 | |
| $1.00 | +0.04 | +4.2% | $1.00 | $1.00 | $0.95 | 4,700 | |
| $0.96 | -0.03 | -3.0% | $0.96 | $0.96 | $0.96 | 100 | |
| $0.99 | -0.01 | -1.0% | $0.91 | $0.99 | $0.91 | 600 | |
| $1.00 | +0.08 | +8.7% | $1.00 | $1.00 | $0.96 | 800 | |
| $0.92 | +0.02 | +2.2% | $0.92 | $0.92 | $0.92 | 100 | |
| $0.90 | +0.19 | +26.8% | $0.90 | $0.90 | $0.90 | 300 | |
| $0.71 | +0.01 | +1.4% | $0.70 | $0.71 | $0.70 | 1,100 | |
| $0.70 | -0.05 | -6.7% | $0.70 | $0.70 | $0.70 | 100 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 2 | |
| $0.75 | -0.07 | -8.5% | $0.70 | $0.78 | $0.70 | 1,700 | |
| $0.82 | 0.00 | 0.0% | $0.82 | $0.82 | $0.82 | 51 | |
| $0.82 | 0.00 | 0.0% | $0.82 | $0.82 | $0.82 | 31 | |
| $0.82 | +0.12 | +17.1% | $0.82 | $0.82 | $0.82 | 200 | |
| $0.70 | 0.00 | 0.0% | $0.70 | $0.70 | $0.70 | 2 | |
| $0.70 | 0.00 | 0.0% | $0.70 | $0.70 | $0.70 | 78 | |
| $0.70 | -0.30 | -30.0% | $0.70 | $0.70 | $0.70 | 200 | |
| $1.00 | -0.01 | -1.0% | $1.00 | $1.00 | $0.66 | 1,200 | |
| $1.01 | 0.00 | 0.0% | $1.01 | $1.01 | $1.01 | 1 | |
| $1.01 | +0.01 | +1.0% | $1.00 | $1.01 | $1.00 | 300 | |
| $1.00 | -0.05 | -4.8% | $1.05 | $1.05 | $1.00 | 1,300 | |
| $1.05 | -0.07 | -6.3% | $1.05 | $1.05 | $1.05 | 300 | |
| $1.12 | -0.02 | -1.8% | $1.12 | $1.12 | $1.12 | 1,100 | |
| $1.14 | 0.00 | 0.0% | $1.14 | $1.14 | $1.14 | 127 | |
| $1.14 | -0.01 | -0.9% | $1.15 | $1.15 | $1.14 | 800 | |
| $1.15 | +0.04 | +3.6% | $1.00 | $1.15 | $1.00 | 1,800 | |
| $1.11 | +0.10 | +9.9% | $1.01 | $1.14 | $1.01 | 3,800 | |
| $1.01 | 0.00 | 0.0% | $1.01 | $1.01 | $1.01 | 500 | |
| $1.01 | -0.02 | -1.9% | $1.01 | $1.01 | $1.01 | 100 | |
| $1.03 | 0.00 | 0.0% | $1.03 | $1.03 | $1.03 | 0 | |
| $1.03 | 0.00 | 0.0% | $1.03 | $1.03 | $1.03 | 1 | |
| $1.03 | -0.01 | -1.0% | $1.03 | $1.03 | $1.03 | 100 | |
| $1.04 | +0.07 | +7.2% | $1.04 | $1.04 | $1.04 | 300 | |
| $0.97 | +0.07 | +7.8% | $0.97 | $0.97 | $0.97 | 100 | |
| $0.90 | -0.10 | -10.0% | $0.90 | $0.90 | $0.90 | 100 | |
| $1.00 | 0.00 | 0.0% | $1.01 | $1.01 | $1.00 | 500 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 500 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 0 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 0 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 300 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 800 | |
| $1.00 | -0.06 | -5.7% | $1.05 | $1.06 | $1.00 | 2,200 | |
| $1.06 | +0.01 | +1.0% | $1.05 | $1.06 | $1.05 | 1,500 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 900 | |
| $1.05 | -0.01 | -0.9% | $1.05 | $1.05 | $1.05 | 1,500 | |
| $1.06 | +0.31 | +41.3% | $0.75 | $1.06 | $0.75 | 10,900 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | -0.25 | -25.0% | $0.75 | $0.75 | $0.75 | 500 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 1 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 1,000 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 300 | |
| $1.00 | +0.28 | +38.9% | $1.00 | $1.00 | $0.99 | 8,000 | |
| $0.72 | 0.00 | 0.0% | $0.72 | $0.72 | $0.72 | 0 | |
| $0.72 | -0.33 | -31.4% | $0.72 | $0.72 | $0.72 | 4,000 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 400 | |
| $1.05 | -0.05 | -4.5% | $1.10 | $1.10 | $1.00 | 5,100 | |
| $1.10 | 0.00 | 0.0% | $1.10 | $1.10 | $1.10 | 0 | |
| $1.10 | +0.10 | +10.0% | $1.12 | $1.12 | $1.10 | 6,900 |
Splits
2 splits since 2023 · OTC:VCNX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-14 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- OTC:VCNX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 7, 2026
SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
Latest news
SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
Oct 7, 2026
Closed $1.15 (+3.6%) on Oct 7, 2026
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
Jul 8, 2026
Closed $1.29 (+15.2%) on Jul 8, 2026
Vaccinex Reports 2025 Annual Financial Results
Apr 29, 2026
Closed $0.78 (0.0%) on Apr 30, 2026
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
Dec 23, 2025
Closed $0.71 (+1.4%) on Dec 23, 2025
Vaccinex, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 4 in the last 12 months · 7 in all · newest Oct 7, 2026 · oldest 2025
- Decks
- 4 decks · latest Sep 13, 2022
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 1.04
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Vaccinex, Inc. · OTC:VCNX | US$2.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.04 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| PharmaCyte Biotech, Inc. · NASDAQ:PMCB | US$2.25M | −US$15.59M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.97 |
| Modus Therapeutics Holding AB · OMXSTO:MODTX | US$2.22M | US$1.00M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Nuformix PLC · LSE:NFX | US$2.22M | US$1.00M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Medicus Pharma Ltd. · NASDAQ:MDCX | US$2.18M | −US$2.73M | n/a | n/a | n/a | n/a | n/a | n/a | 2.03 |
| Senti Biosciences Holdings, Inc. · NASDAQ:SNTI | US$2.06M | −US$3.49M | n/a | −47.2× | n/a | n/a | n/a | n/a | 2.91 |
| CASI Pharmaceuticals, Inc. · OTC:CASIF | US$2.06M | US$38.79M | n/a | 1.9× | n/a | n/a | −218.6% | n/a | -0.07 |
| Vectus Biosystems Limited · ASX:VBS | US$2.02M | US$50,946 | 1.9× | n/a | n/a | 1.3× | n/a | 0.2× | n/a |
| Decoy Therapeutics Inc. · NASDAQ:DCOY | US$1.98M | −US$6.19M | n/a | −11.6× | n/a | 0.4× | n/a | 0.0× | 1.28 |
| Median of the others | US$2.20M | −US$1.34M | 1.9× | −5.0× | 0.8× | −379.5% | 0.0× | 1.63 |
Team and board
Officers
| Officer | Role |
|---|---|
| Maurice Zauderer | President and CEO |
| Jill Sanchez | Chief Financial Officer |
| Elizabeth Evans | COO & Senior Vice President, Discovery and Translational Science |
Board
| Director | Role |
|---|---|
| Albert D. Friedberg | Chairman of the Board |
| Jacob B. Frieberg | Board Member |
| Maurice Zauderer | President and CEO |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2025 | May 9, 2025 · After close | +44.1% |
| Q3 2024 | Nov 11, 2024 · Before open | +3.9% |
| Q2 2024 | Aug 12, 2024 · Before open | +4.6% |
| Q1 2024 | Apr 2, 2024 · Before open | −3.6% |
| Q3 2023 | Nov 13, 2023 · Before open | −1.1% |
| Q2 2023 | Aug 14, 2023 · Before open | −7.7% |
| Q1 2023 | May 15, 2023 · After close | −7.5% |
| Q4 2022 | Mar 31, 2023 · After close | +5.0% |
| Q3 2022 | Nov 14, 2022 · Before open | −1.7% |
| Q2 2022 | Aug 15, 2022 · After close | −2.8% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2022 | May 16, 2022 · Before open | −0.8% |
| Q4 2021 | Mar 31, 2022 · Before open | 0.0% |
| Q3 2021 | Nov 8, 2021 · Before open | −2.0% |
| Q2 2021 | Aug 16, 2021 · Before open | −4.3% |
| Q1 2021 | May 17, 2021 · Before open | +2.4% |
| Q4 2020 | Mar 31, 2021 · Before open | −2.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2022) | Technical | 12 slides | Sep 13, 2022 |
| Corporate Update (June 2022) | Corporate update | 16 slides | Jun 10, 2022 |
| Investor Presentation (March 2019) | Investor deck | 32 slides | Mar 18, 2019 |
| Investor Presentation (September 2018) | Investor deck | 30 slides | Sep 26, 2018 |
Financings
| Raise | Date |
|---|---|
| Revenue sharing agreement Announced: US$60M Buyers: Pepinemab Development Venture, LP ($60 million funding commitment in exchange for 50% of future economic proceeds from pepinemab neurological indications and 25% from other indications) Insiders: PDV is an investment entity established by FCMI, an existing Vaccinex investor; Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. Use of proceeds: Advance development of pepinemab in an enlarged phase 2b clinical trial for Alzheimer's disease | Dec 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$12.00 a share on Aug 9, 2018.
- Price
- US$12.00 a share
- Shares offered
- 3,333,334 shares of common stock
- Offering size
- US$40 million
- Underwriters' option
- Up to 500,000 more shares
- Underwriters
- Oppenheimer & Co., BTIG, Ladenburg Thalmann · In the order on the cover
- Shares delivered
- On or about Aug 13, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 13, 2018 |
| Filed publicly | Jul 9, 2018 |
| Amended twice | Newest Aug 8, 2018 |
| Shares registered with an exchange | Aug 8, 2018 |
| Declared effective by the SEC | Aug 9, 2018 |
| Final prospectus, with the price | Aug 10, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 10, 2018 |
| EFFECT · Notice that a registration is effective | Aug 9, 2018 |
| CERT · Exchange's certificate of listing | Aug 8, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 8, 2018 |
| S-1/A · Registration statement, amended | Aug 8, 2018 |
| CORRESP · Letter to the SEC | Aug 6, 2018 |
| CORRESP · Letter to the SEC | Aug 6, 2018 |
| S-1/A · Registration statement, amended | Jul 23, 2018 |
| CORRESP · Letter to the SEC | Jul 9, 2018 |
| S-1 · Registration statement | Jul 9, 2018 |
All 16 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jun 20, 2018 |
| DRSLTR · Letter to the SEC with a draft | Jun 8, 2018 |
| DRS/A · Draft registration statement, amended | Jun 8, 2018 |
| UPLOAD · Letter from the SEC | May 11, 2018 |
| DRSLTR · Letter to the SEC with a draft | Apr 13, 2018 |
| DRS · Draft registration statement | Apr 13, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 10, 2018
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 601.0K | 570.0K | 275.0K | 900.0K | 625.0K | 523.0K | 724.0K | 90.0K | |
| Cost of revenue | 2.00K | 199.0K | 1.03M | 160.0K | |||||
| Gross profit | 623.0K | 324.0K | -309.0K | -70.0K | |||||
| Research and development | 12.5M | 16.6M | 14.0M | 17.2M | 21.5M | 25.7M | 22.4M | 16.6M | |
| Operating income | -18.7M | -22.9M | -19.9M | -22.5M | -28.3M | -32.0M | -27.3M | -21.1M | |
| Depreciation and amortization | 94.0K | 119.0K | 207.0K | 169.0K | 307.0K | 249.0K | 223.0K | 206.0K | |
| EBITDA | -18.6M | -22.8M | -19.7M | -22.3M | -28.0M | -31.8M | -27.1M | -20.9M | |
| Interest expense | 2.00K | 1.00K | 2.00K | 809.0K | 489.0K | 392.0K | 1.36M | ||
| Income before tax | -18.6M | -20.3M | -19.8M | -22.4M | -28.9M | -31.9M | -29.5M | -18.8M | |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -18.6M | -20.3M | -19.8M | -22.4M | -28.9M | -31.9M | -29.5M | -18.7M | |
| Earnings per share, basic | -8.88 | -43.68 | -98.05 | -0.78 | -1.54 | -2.47 | -5.65 | -19.90 | |
| Earnings per share, diluted | -8.88 | -43.68 | -98.05 | -0.78 | -1.54 | -2.47 | -5.65 | -19.90 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.11M | 1.53M | 6.39M | 8.59M | 10.6M | 2.78M | 5.62M | 4.18M | 1.66M |
| Short-term investments | 0 | 14.1M | |||||||
| Receivables | 838.0K | 961.0K | 175.0K | 157.0K | 898.0K | 639.0K | 117.0K | ||
| Current assets | 2.53M | 3.35M | 7.48M | 9.40M | 11.3M | 4.01M | 21.4M | 4.97M | |
| Property, plant and equipment | 65.0K | 136.0K | 189.0K | 297.0K | 416.0K | 594.0K | 604.0K | 601.0K | |
| Total assets | 2.60M | 3.63M | 7.98M | 9.84M | 11.7M | 4.60M | 22.0M | 5.58M | |
| Accounts payable | 3.96M | 2.04M | 1.52M | 1.06M | 3.17M | 3.21M | 2.32M | 1.91M | |
| Current liabilities | 5.08M | 5.92M | 2.54M | 2.26M | 13.2M | 6.88M | 6.69M | 4.17M | |
| Long-term debt | 0 | 26.0K | 101.0K | 175.0K | 1.13M | ||||
| Total debt | 25.0K | 101.0K | 175.0K | 249.0K | 1.13M | ||||
| Total liabilities | 5.08M | 5.94M | 2.78M | 2.43M | 14.3M | 6.88M | 6.69M | 7.35M | |
| Shareholders' equity | -2.49M | -2.31M | 5.19M | 7.41M | -26.6M | -26.2M | -8.62M | -125.5M | -107.1M |
| Shares outstanding | 2.68M | 892.6K | 237.5K | 30.8M | 22.4M | 14.9M | 11.5M | 1.10M | 11.5M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -16.2M | -21.4M | -19.1M | -25.3M | -28.6M | -30.7M | -25.3M | -21.4M |
| Capital spending | -22.0K | -67.0K | -99.0K | -32.0K | -290.0K | -78.0K | -235.0K | -68.0K |
| Free cash flow | -16.2M | -21.4M | -19.2M | -25.3M | -28.9M | -30.8M | -25.5M | -21.5M |
| Cash from investing | -22.0K | -67.0K | -99.0K | -32.0K | -290.0K | 14.1M | -14.2M | -68.0K |
| Cash from financing | 15.8M | 16.6M | 17.0M | 23.3M | 36.8M | 13.8M | 41.0M | 24.0M |
| Change in cash | -428.0K | -4.86M | -2.20M | -2.01M | 7.82M | -2.84M | 1.44M | 2.52M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-K · Annual report | Apr 15, 2025 | Annual report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2025 | Explanation request | SEC |
| 15-12G | Mar 27, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 25, 2025 | Offer document | SEC |
| S-8 POS | Mar 25, 2025 | Offer document | SEC |
| S-8 POS | Mar 25, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 19, 2025 | Management or board change | SEC |
| 25 | Mar 17, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 7, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Oct 25, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 21, 2024 | Other filings | SEC |
| S-3 · Registration statement | Oct 16, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 9, 2024 | Current report | SEC |
| D | Sep 27, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 20, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 19, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 13, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 20, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 31, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jul 8, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 2, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 1, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jun 27, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 6, 2024 | Current report | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | May 14, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 14, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 14, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 13, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 10, 2024 | Offer document | SEC |
| 424B3 · Prospectus | May 9, 2024 | Offer document | SEC |
| 8-K · Current report | May 9, 2024 | Meeting outcome | SEC |
| S-3/A · Registration statement, amended | May 8, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 2, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 2, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 26, 2024 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 25, 2024 | Annual report | SEC |
| 4 · Change in ownership | Apr 22, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Apr 16, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 12, 2024 | Other filings | SEC |
| D | Apr 12, 2024 | Other filings | SEC |
| D | Apr 12, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 12, 2024 | Current report | SEC |
| D | Apr 12, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 2, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 2, 2024 | Meeting notice | SEC |
| S-3 · Registration statement | Apr 2, 2024 | Offer document | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2024 | Explanation request | SEC |
| 8-K · Current report | Apr 1, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 28, 2024 | Current report | SEC |
| 424B5 · Prospectus | Mar 28, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 27, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 21, 2024 | Current report | SEC |
| 8-K · Current report | Feb 15, 2024 | Current report | SEC |
| 8-K · Current report | Feb 13, 2024 | Meeting outcome | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Feb 8, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 7, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jan 22, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jan 19, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 17, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 16, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jan 10, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Jan 8, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 28, 2023 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Dec 28, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 26, 2023 | Current report | SEC |
| 4 · Change in ownership | Oct 25, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 18, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 12, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 11, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 4, 2023 | Material contract | SEC |
| 424B4 · Prospectus | Oct 2, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 29, 2023 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Sep 28, 2023 | Offer document | SEC |
| 8-K · Current report | Sep 27, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 26, 2023 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 26, 2023 | Current report | SEC |
| S-1/A · Registration statement, amended | Sep 26, 2023 | Offer document | SEC |
| 4 · Change in ownership | Sep 25, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 22, 2023 | Current report | SEC |
| 8-K · Current report | Sep 22, 2023 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Sep 20, 2023 | Other filings | SEC |
| S-1 · Registration statement | Sep 14, 2023 | Offer document | SEC |
| 8-K · Current report | Sep 13, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Aug 22, 2023 | Material contract | SEC |
| DEF 14A · Proxy statement | Aug 14, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Aug 4, 2023 | Meeting notice | SEC |
| 424B3 · Prospectus | Jul 11, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 11, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 7, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 20, 2023 | Other filings | SEC |
| S-3 · Registration statement | Jun 14, 2023 | Offer document | SEC |
| 8-K · Current report | May 30, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | May 25, 2023 | Big-stake notice | SEC |
| 8-K · Current report | May 19, 2023 | Current report | SEC |
| 424B5 · Prospectus | May 19, 2023 | Offer document | SEC |
| 4 · Change in ownership | May 16, 2023 | Insider trade | SEC |
| 8-K · Current report | May 15, 2023 | Material contract | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 8-K · Current report | May 12, 2023 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Apr 13, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 10, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2023 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 6, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 6, 2023 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 5, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
This page holds 200 of 475 filings. Open Filings
Cap table
Built by 6ix from Vaccinex, Inc.’s releases · as of Dec 31, 2025
- Common shares
- 2,676,637
- Fully diluted
- 2,676,637
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,676,637 | Dec 31, 2025 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,676,637 |
| Dec 31, 2025 | 2,098,900 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jeff Goater Other companies: LogicBio Therapeutics Inc (Director · Dec 10, 2020 – Nov 16, 2022 · Past); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past) | Director · Aug 9, 2018 – May 11, 2021 · Past |
| Albert D. Friedberg | Chairman of the Board · Since at least Oct 3, 2023 |
| Elizabeth Evans | COO & Senior Vice President, Discovery and Translational Science · Since at least Oct 7, 2026 |
| Ernest S Smith | SVP, Research & CSO · Apr 1, 2022 – Mar 21, 2024 · Past |
| Gerald E Van Strydonck | Director · Aug 9, 2018 – May 10, 2024 · Past |
| Jacob B. Frieberg | Board Member · Since at least Aug 9, 2018 |
| Jill Sanchez | Chief Financial Officer · Since at least Nov 5, 2026 |
| John E Leonard | SVP, Development · Aug 9, 2018 – Mar 31, 2023 · Past |
| Maurice Zauderer | President and CEO · Since at least Nov 5, 2026 |
| Scott E Royer | Chief Financial Officer · Apr 1, 2022 – Mar 31, 2023 · Past |
Log in to ask 6ix AI your own questions about Vaccinex, Inc.